Equity Components [Axis] Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Class of Stock [Axis] Series C 0% Convertible Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series A Preferred Stock [Member] Restatement [Axis] Previously Reported [Member] Restatement Adjustment [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Award Type [Axis] Employee Stock Option [Member] Warrant [Member] Short-term Debt, Type [Axis] Convertible debentures [Member] Series A 0% Convertible Preferred Stock [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Related Party [Axis] Dr. Richerson [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Separation Agreement [Member] Consultant [Member] Plan Name [Axis] Financing 2014 [Member] Financing 2015 [Member] Financing 2016 [Member] Financings 2017 [Member] Series B And Series C Preferred Stock [Member] Income Statement Location [Axis] Research And Development [Member] General And Administrative [Member] Measurement Input, Expected Term [Member] Exchange Agreement [Member] Investors [Member] Long-term Debt, Type [Axis] 10% Convertible Promissory Notes [Member] Debt Instrument [Axis] Series B 0% Convertible Preferred Stock [Member] SeriesAConvertiblePreferredStockMember Series D 0% Convertible Preferred Stock [Member] Registration Rights Agreement [Member] Share Exchange Agreement [Member] Business Acquisition [Axis] Lewis & Clark Pharmaceuticals, Inc. [Member] Escrow Agreement [Member] Preferred Stock And Warrants [Member] Convertible Debentures [Member] Property, Plant and Equipment, Type [Axis] Office And Lab Equipment [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity's Reporting Status Current Entity Emerging Growth Company Entity Small Business Entity Filer Category Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Restricted cash Prepaid expenses Total current assets Office and lab equipment, net of accumulated depreciation of $4 and $2, respectively Intangible assets, net of accumulated amortization of $175 and $162, respectively Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable Accrued expenses Convertible debentures, net of unamortized discount of $386 and $227, respectively Derivative liability Total current liabilities Total liabilities Commitments and contingencies (Note 7) Stockholders' deficit: Convertible preferred stock, par value $.0001 per share; 30,000,000 shares authorized, 495 and 495 shares issued and outstanding, respectively Common stock, par value $.0001 per share; 150,000,000 shares authorized, 21,388,929 and 10,888,929 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Office and lab equipment, accumulated depreciation Intangible assets, accumulated amortization Net of unamortized discount of, convertible debentures Convertible preferred stock, par value (in dollars per share) Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income (expense): (Loss) gain on change in fair value of derivative liability Gain on conversion of debt Interest (expense), net Loss before provision for income taxes Provision for income taxes Net loss Deemed dividend Net loss attributable to common shareholders Net loss per common share, basic and diluted Weighted average shares outstanding Statement [Table] Statement [Line Items] Convertible Preferred Stock Shares Common Stock Shares Additional Paid-in Capital Accumulated Deficit Balance at beginning Balance at beginning (in shares) Stock-based compensation Conversion of preferred stock to common stock Conversion of preferred stock to common stock (in shares) Preferred stock exchanged for convertible notes payable Preferred stock exchanged for convertible notes payable (in shares) Conversion of notes Conversion of notes (in shares) Common stock issued for acquisition Common stock issued for acquisition (in shares) Sale of preferred stock and warrants Sale of preferred stock and warrants (in shares) Preferred stock and warrants issued for services Preferred stock and warrants issued for services (in shares) Conversion of debentures Conversion of debentures (in shares) Net loss Balance at ending Balance at ending (in shares) Statement of Stockholders' Equity [Abstract] Share price (in dollars per share) Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Loss (gain) on change in fair value of derivative liability Gain on conversion of debt Amortization of debt discount Finance cost Decrease in operating assets: Prepaid expenses Increase in operating liabilities: Accounts payable and accrued expenses Cash used in operating activities Cash flows from investing activities: Cash from acquisition Acquisition of office equipment Cash provided by investing activities Cash flows from financing activities: Proceeds from convertible notes Proceeds from sale of stock and warrants Cash provided by financing activities Net increase (decrease) in cash and restricted cash Cash and restricted cash, beginning of period Cash and restricted cash, end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] BACKGROUND Management Plans to Continue as Going Concern [Abstract] MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN Accounting Policies [Abstract] SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL CASH FLOW INFORMATION Accrued Liabilities, Current [Abstract] ACCRUED EXPENSES Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Stockholders' Equity Note [Abstract] CAPITAL STOCK AND STOCKHOLDER'S EQUITY Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK OPTIONS Warrants WARRANTS Debt Disclosure [Abstract] CONVERTIBLE DEBENTURES Business Combinations [Abstract] ACQUISITION Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates Research and Development Cash Equivalents Restricted Cash Loss per Share Derivative Liability Fair Value of Financial Instruments Fair Value Measurements Stock-Based Compensation Effect of ASU No. 2017-11 on Previously Issued Financial Statements Recent Accounting Pronouncements Schedule of weighted average shares outstanding Schedule of fair values of financial liabilities Schedule of fair value of derivative liability on recurring basis Schedule of financial statements Schedule of additional information of cash flow Schedule of accrued expenses Schedule of black scholes valuations of derivatives Schedule of stock-based compensation expense Schedule of stock option activity Schedule of transactions involving of warrants Schedule of outstanding warrants to purchase common stock Schedule of final accounting Schedule of pro forma result of acquisition Background (Textual) Proceeds from sale of debt securities Proceeds from sale of notes Management's Plans to Continue as a Going Concern (Textual) Cash and cash equivalents and restricted cash balances Percentage of total assets Amount raised Shares underlying options outstanding [Member] Shares underlying convertible notes outstanding [Member] Shares underlying convertible preferred stock outstanding [Member] Shares underlying warrants outstanding [Member] Shares underlying, outstanding Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Derivative liability Balance at beginning of year Additions to derivative instruments Reclassification on conversion Loss (gain) on change in fair value of derivative liability Balance at end of period As reported [Member] Adjustments [Member] Cash and cash equivalents Total current assets Office and lab equipment, net of accumulated depreciation of $10 Intangible assets, net of accumulated amortization of $158 Goodwill Other assets Total assets Convertible debentures, net of unamortized discount of $307 Total current liabilities Total liabilities Commitments and contingencies Convertible preferred stock, par value $.0001 per share; 30,000,000 shares authorized, 495 shares issued and outstanding Common stock, par value $.0001 per share; 150,000,000 shares authorized, 9,075,589 shares issued and outstanding Total stockholders' deficit Total liabilities and stockholders' deficit Total operating expenses Loss from operations Gain on change in fair value of derivative liability Gain on conversion of debt Interest income (expense), net Loss before provision for income taxes Deemed dividend Net loss attributable to common shareholders Net loss per common share, basic and diluted (in dollars per share) Weighted average shares outstanding (in shares) Gain on change in fair value of derivative liability Gain on conversion of debt Amortization of debt discount Increase in operating assets: Prepaid expenses Cash used in operating activities Cash from acquisition Cash provided by investing activities Proceeds from convertible notes Cash provided by financing activities Net decrease in cash Cash, beginning of period Cash, end of period Summary of Critical Accounting Policies and Use of Estimates (Textual) Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability Debentures converted to common stock Derivative liability extinguished upon conversion of notes payable Derivative liability issued Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. Accounts payable paid through issuance of debentures Debentures issued to retire preferred stock Accrued compensation and benefits Accrued research and development Accrued other Total accrued expenses Volatility [Member] Expected term (years) [Member] Risk-free interest rate [Member] Dividend yield [Member] Derivative liability measurement input Derivative liability term Derivative Liability (Textual) Gain on change in fair value of the derivative liability Derivative Liability Commitments and Contingencies (Textual) Rent expenses Warrants issued to purchase common stock Exercise price (in dollars per share) Option excersice price (in dollars per share) Warrant expiration period Gross proceeds from capital raising transactions Series A Convertible Preferred Stock [Member] Capital Stock and Stockholders' Equity (Textual) Stock issued during period, shares Value of number of shares issued Conversion price (in dollars per share) Reduction in conversion price (in dollars per share) Number of shares issued upon conversion Principal amount of senior convertible debentures Number of shares converted Amount of debentures converted Number of common shares purchased Preferred stock, par value (in dollars per share) Securities sold Amount of conversion convertible debentures Number of conversion convertible debentures (in shares) Percentage of shares acquired Preferred stock, outstanding Beneficial ownership limitation Deemed dividend Research and development [Member] General and administrative [Member] Total stock-based compensation expense Number of shares Outstanding at beginning Granted Forfeited Outstanding at ending Exercisable at ending Weighted-average exercise price Outstanding at beginning Granted Forfeited Outstanding at ending Exercisable at ending Weighted-average remaining contractual term (in years) Outstanding at ending Exercisable at ending Aggregate intrinsic value (in thousands) Outstanding at ending Exercisable at ending Number of shares Outstanding at beginning Issued Expired Outstanding at ending Exercisable at ending Weighted-average exercise price Outstanding at beginning Issued Expired Outstanding at ending Exercisable at ending Weighted-average remaining contractual term Outstanding at ending Aggregate intrinsic value Number of shares Weighted Average Exercise price Expiration date begenning Expiration date ending Warrants (Details Textual) Convertible Debentures (Textual) Common stock,issued Common stock,value Amount of shares converted Payment or cancellation debt Proceeds from debt Received cash from debt Conversion price Maturity date Discreiption of convertible debentures Percentage of outstanding debentures Percentage of partial liquidated damages fee for each investor Percentage of securities issued investors Securities purchase agreements, description Debentures, description Investors holding, description Ownership percentage Cash Prepaid expenses Equipment Total assets acquired Accounts payable and other liabilities Total Revenue Net loss attributable to common shareholders Net loss per share Acquisition (Textual) Percentage of ownership acquired Number of shars issued upon acquistion (Purchase consideration) Number of shares issued upon acquistion, value (Purchase consideration) Number of shares held in escrow account Number of shares received by shareholders (5% of the payment shares) Value of revenue and loss Value of revenue and loss Goodwill impairment charge Asset impairment charge Face amount Debt face amount in cash Interest rate Maturity date, description Terms of conversion feature Number of common shares issued Preferred stock, designated shares Preferred stock, par value Preferred stock, stated value Reverse stock split Shares issued Proceeds from convertible preferred stock Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Percentage of beneficial ownership limitation. Change in fair value of derivative liability during the period. Information by type of related party. Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Amount of dividend payable by entity. Disclosure of accounting policy pertaining to previously accounting pronouncements. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. It represents as a expiration date begenning. It represents as a expiration date ending. It refers to the amount of liability reclassified as fair value. It represents the amount of finance cost paid during the period. Information by plan name pertaining to equity-based compensation arrangements. Information by plan name pertaining to equity-based compensation arrangements. Information by plan name pertaining to equity-based compensation arrangements. Information by plan name pertaining to equity-based compensation arrangements. Information by plan name pertaining to equity-based compensation arrangements. Value of gross proceeds from capital raising transactions. Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Information by business combination or series of individually immaterial business combinations. The entire disclosure of management plans to continue as a going concern. It represents of number of shares held in escrow account. It represents of number of shares received by shareholders. It represents of payment from convertible debt cash received. It represents of percentage of outstanding debentures. It represents of percentage of partial liquidated damages fee for each investor. It represents of percentage of securities issued investors. Share of preferred stock and warrants issued during the period. Value of preferred stock and warrants issued during the period. This member stands for preferred stock and warrants by entity. Preferred stock conversion price per common share. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. Information by category of arrangement, Information by type of debt instrument, including, but not limited to, draws against credit facilities. This member stands for series B and C preferred stock by entity. Information by type of debt instrument, including, but not limited to, draws against credit facilities. Information by the different classes of stock of the entity. Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. The number of shares into which fully or partially vested equity intrument other than options exercisable as of the balance sheet date. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of equity instruments other than options outstanding and currently exercisable under the stock option plan. The weighted average exercise price forfeited for warrants during the period. The weighted average exercise price granted for warrants during the period. The number of equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. The weighted average exercise price for outstanding warrants. A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. Number of shares issued during period of conversion of notes. Value of stock issued during period of conversion of notes. Represents the warrants expiration period. The entire disclosure for warrant. It represents the amount of warrants issued to purchase shares of common stock. Disclosure of accounting policy for restricted cash. Percentage of total assets. Amount raised. The amount of gain loss on conversion of debt. Derivative liability issued. Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. Accounts payable paid through issuance of debentures. Debentures issued to retire preferred stock. Derivative liability measurement input percentage. Value of preferred stock exchanged for convertible notes payable. Number of preferred stock exchanged for convertible notes payable. Value of conversion of notes. Number of conversion of notes. Amount of common stock issued for acquisition. Number of common stock issued for acquisition. It represents the amount of loss (gain) on change in fair value of derivative liability. The cash outflow to acquire for cash. The cash inflow from convertible notes Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. It represents the amount of goodwill impairment charge. Preferred Stock Dividends and Other Adjustments Shares, Outstanding Share-based Compensation LossGainOnChangeInFairValueOfDerivativeLiability Increase (Decrease) in Prepaid Expense PaymentsToAcquireForCash Payments to Acquire Property, Plant, and Equipment Derivative Liability [Default Label] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value GainsLossesOnConversionOfDebt Redeemable Preferred Stock Dividends Change in Fair Value Of Derivative Liability Amortization of Debt Discount (Premium) Increase (Decrease) in Prepaid Expense and Other Assets Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber Weighted-average exercise price [Roll Forward] ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Class of Warrant or Right, Outstanding Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Acquisition, Pro Forma Net Income (Loss) Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual